Literature DB >> 32040748

[Axial spondyloarthritis and psoriatic arthritis : Current results and assessments].

J Braun1.   

Abstract

Entities:  

Mesh：

Year:  2020        PMID： 32040748     DOI： 10.1007/s00393-020-00753-y

Source DB:  PubMed          Journal:  Z Rheumatol        ISSN： 0340-1855            Impact factor:   1.372


× No keyword cloud information.
  30 in total

1.  Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis.

Authors:  Dominique Baeten; Joachim Sieper; Jürgen Braun; Xenofon Baraliakos; Maxime Dougados; Paul Emery; Atul Deodhar; Brian Porter; Ruvie Martin; Mats Andersson; Shephard Mpofu; Hanno B Richards
Journal:  N Engl J Med       Date:  2015-12-24       Impact factor: 91.245

2.  Active and chronic sacroiliitis, spondylitis and enthesitis, How specific are imaging findings for axial spondyloarthritis?

Authors:  Juergen Braun; Xenofon Baraliakos
Journal:  Rheumatology (Oxford)       Date:  2019-08-01       Impact factor: 7.580

3.  Effects of ustekinumab versus tumor necrosis factor inhibition on enthesitis: Results from the enthesial clearance in psoriatic arthritis (ECLIPSA) study.

Authors:  Elizabeth G Araujo; Matthias Englbrecht; Sabrina Hoepken; Stephanie Finzel; Eleni Kampylafka; Arnd Kleyer; Sarah Bayat; Verena Schoenau; Axel Hueber; Juergen Rech; Georg Schett
Journal:  Semin Arthritis Rheum       Date:  2018-06-13       Impact factor: 5.532

4.  The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection.

Authors:  M Rudwaleit; D van der Heijde; R Landewé; J Listing; N Akkoc; J Brandt; J Braun; C T Chou; E Collantes-Estevez; M Dougados; F Huang; J Gu; M A Khan; Y Kirazli; W P Maksymowych; H Mielants; I J Sørensen; S Ozgocmen; E Roussou; R Valle-Oñate; U Weber; J Wei; J Sieper
Journal:  Ann Rheum Dis       Date:  2009-03-17       Impact factor: 19.103

5.  Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis.

Authors:  J Braun; M Bollow; L Neure; E Seipelt; F Seyrekbasan; H Herbst; U Eggens; A Distler; J Sieper
Journal:  Arthritis Rheum       Date:  1995-04

6.  Efficacy and safety of continuing versus withdrawing adalimumab therapy in maintaining remission in patients with non-radiographic axial spondyloarthritis (ABILITY-3): a multicentre, randomised, double-blind study.

Authors:  Robert Landewé; Joachim Sieper; Philip Mease; Robert D Inman; Robert G Lambert; Atul Deodhar; Helena Marzo-Ortega; Marina Magrey; Uta Kiltz; Xin Wang; Mei Li; Sheng Zhong; Nael M Mostafa; Apinya Lertratanakul; Aileen L Pangan; Jaclyn K Anderson
Journal:  Lancet       Date:  2018-06-29       Impact factor: 79.321

7.  Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study.

Authors:  Dominique Baeten; Mikkel Østergaard; James Cheng-Chung Wei; Joachim Sieper; Pentti Järvinen; Lai-Shan Tam; Carlo Salvarani; Tae-Hwan Kim; Alan Solinger; Yakov Datsenko; Chandrasena Pamulapati; Sudha Visvanathan; David B Hall; Stella Aslanyan; Paul Scholl; Steven J Padula
Journal:  Ann Rheum Dis       Date:  2018-06-26       Impact factor: 19.103

8.  A Fifty-Two-Week, Randomized, Placebo-Controlled Trial of Certolizumab Pegol in Nonradiographic Axial Spondyloarthritis.

Authors:  Atul Deodhar; Lianne S Gensler; Jonathan Kay; Walter P Maksymowych; Nigil Haroon; Robert Landewé; Martin Rudwaleit; Stephen Hall; Lars Bauer; Bengt Hoepken; Natasha de Peyrecave; Brian Kilgallen; Désirée van der Heijde
Journal:  Arthritis Rheumatol       Date:  2019-05-28       Impact factor: 10.995

9.  Development of ASAS quality standards to improve the quality of health and care services for patients with axial spondyloarthritis.

Authors:  Uta Kiltz; Robert B M Landewé; Désirée van der Heijde; Martin Rudwaleit; Michael H Weisman; Nurullah Akkoc; Annelies Boonen; Jan Brandt; Philippe Carron; Maxime Dougados; Laure Gossec; Merryn Jongkees; Pedro M Machado; Helena Marzo-Ortega; Anna Molto; Victoria Navarro-Compán; Karin Niederman; Percival Degrava Sampaio-Barros; Gleb Slobodin; Filip E Van den Bosch; Astrid van Tubergen; Salima van Weely; Dieter Wiek; Juergen Braun
Journal:  Ann Rheum Dis       Date:  2019-10-11       Impact factor: 19.103

10.  Secukinumab shows sustained efficacy and low structural progression in ankylosing spondylitis: 4-year results from the MEASURE 1 study.

Authors:  Jürgen Braun; Xenofon Baraliakos; Atul Deodhar; Denis Poddubnyy; Paul Emery; Eumorphia M Delicha; Zsolt Talloczy; Brian Porter
Journal:  Rheumatology (Oxford)       Date:  2019-05-01       Impact factor: 7.580
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.